Article
Biochemistry & Molecular Biology
Eva Juengel, Pascal Schnalke, Jochen Rutz, Sebastian Maxeiner, Felix K. -H. Chun, Roman A. Blaheta
Summary: Axitinib significantly suppressed the growth of sunitinib-resistant HUVECs and induced cell cycle arrest at the G0/G1 phase. Both axitinib and sorafenib reduced HUVEC tube length and prevented wound closure in sunitinib-resistant HUVECs after six weeks of treatment, with sorafenib showing slightly better results.
Article
Oncology
Catherine Leyh, Ursula Ehmer, Daniel Roessler, Alexander B. Philipp, Florian P. Reiter, Petia Jeliazkova, Leonie S. Jochheim, Matthias Jeschke, Janina Hammig, Johannes M. Ludwig, Jens M. Theysohn, Andreas Geier, Christian M. Lange
Summary: This study compared the sequential systemic therapy after first-line therapy with sorafenib or lenvatinib and discontinuation of therapy in patients with liver cancer. The results showed that liver functional status and patient performance status at the beginning of first-line therapy had an impact on median overall survival (mOS), while the choice of the initial tyrosine kinase inhibitor (TKI) did not affect mOS.
Article
Oncology
Yan Sun, Liang Zhu, Pian Liu, Huan Zhang, Feng Guo, Xin Jin
Summary: In this study, researchers found that the upregulation of palmitoyl acyltransferase ZDHHC2 is associated with TKI resistance in ccRCC. ZDHHC2 mediates AGK S-palmitoylation to activate the PI3K-AKT-mTOR signaling pathway, which modulates sunitinib sensitivity. These findings suggest that targeting ZDHHC2 may improve the efficacy of sunitinib in treating ccRCC.
Article
Medicine, General & Internal
T. K. Choueiri, T. Powles, M. Burotto, B. Escudier, M. T. Bourlon, B. Zurawski, V. M. Oyervides Juarez, J. J. Hsieh, U. Basso, A. Y. Shah, C. Suarez, A. Hamzaj, J. C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J. P. Feregrino, J. Zolnierek, D. Pook, E. R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M. A. Maurer, B. Simsek, F. Ejzykowicz, G. M. Schwab, A. B. Apolo, R. J. Motzer
Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, Nadine Houede, Brigitte Laguerre, Giuseppe Procopio, Stephanie Lheureux, R. Fischer, Sylvie Negrier, Alain Ravaud, Stephane Oudard, Bernard Escudier, Laurence Albiges, Camillo Porta
Summary: The study investigated the benefit of using other tyrosine kinase inhibitors (TKIs) or mTOR inhibitors for mRCC patients who did not respond well to first-line sunitinib treatment. The results showed minimal benefit in using further TKIs or mTOR inhibitors for these primary refractory patients.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Oncology
Ondrej Fiala, Pavel Ostasov, Aneta Rozsypalova, Milan Hora, Ondrej Sorejs, Jan Sustr, Barbora Bendova, Ivan Travnicek, Jan Filipovsky, Jindrich Finek, Tomas Buchler
Summary: The retrospective study analyzed clinical data from 343 patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib or pazopanib, and found that the use of metformin was associated with significantly longer progression-free survival (PFS) and overall survival (OS) compared to non-users. The Cox multivariate analysis confirmed that metformin use remained a significant factor for both PFS and OS, indicating a favorable outcome for mRCC patients receiving sunitinib or pazopanib treatment.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Ana Elena Martin-Aguilar, Haide Nunez-Lopez, Juan C. Ramirez-Sandoval
Summary: Sequential inhibition of the VEGF pathway with sorafenib as a second-line therapy shows activity and tolerability in patients with metastatic RCC, especially benefiting those over 65 years old. Adverse events grade >= 3 were mainly observed in 29% of patients.
Review
Oncology
Stephanie. A. A. Berg, Bradley. A. A. McGregor
Summary: This article discusses the treatment options and methods for clear cell renal cell carcinoma after radical nephrectomy. Currently, oral vascular endothelial growth factor receptor tyrosine kinase inhibitors or intravenous immune checkpoint inhibitors are the approved treatments, although they can cause toxic reactions. Multiple clinical trials are currently underway to explore the role of adjuvant treatment after nephrectomy, and biomarkers may help determine the effectiveness of treatments for patients.
Review
Biochemistry & Molecular Biology
Federica Cosso, Giandomenico Roviello, Gabriella Nesi, Sonia Shabani, Pietro Spatafora, Donata Villari, Martina Catalano
Summary: Renal cell carcinoma (RCC) is the third most common genitourinary cancer and has significant mortality rates. Adjuvant therapy has been explored, but the results for both tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs) have been conflicting. Biomarker identification and subgroup analyses are needed to determine which patients can benefit from adjuvant therapy. This review discusses the rationale for adjuvant treatment in RCC and summarizes the current trials and future directions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Andrew L. Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita-Saavedra, Landon C. Brown, Chester Kao, Emily N. Kinsey, Rajan T. Gupta, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T. Campbell
Summary: This case series reported the off-label use of combination TKI-IO for mRCC patients post-first-line therapy, showing that TKI-IO combinations, particularly N+P and N+C, were well tolerated and effective. Some patients achieved significant disease control after first-line treatment with TKI-IO combinations.
Article
Oncology
Alex Renner, Carlos Rojas, Annerleim Walton-Diaz, Mauricio Burotto
Summary: Localized renal cell carcinoma can be cured with surgery, but some patients have a high risk of relapse and may need additional treatment. Previous efforts to find effective strategies have mostly been unsuccessful, but recent results with immune checkpoint inhibitors may change the current standard. Ongoing trials are exploring new alternatives for adjuvant therapy in renal cell carcinoma.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry Mori, Megan Hinkley, Scott S. Tykodi, Evan Hall, John A. Thompson, Ming Yin
Summary: The combination of immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) is a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC), but its efficacy and toxicity beyond the first-line setting are still uncertain.
Article
Biochemistry & Molecular Biology
Filipa Amaro, Carolina Pisoeiro, Maria Joao Valente, Maria de Lourdes Bastos, Paula Guedes de Pinho, Marcia Carvalho, Joana Pinto
Summary: This study compared the different cellular and metabolic responses of sunitinib and pazopanib in treating metastatic renal cell carcinoma, suggesting that sunitinib has better in vitro efficacy against target RCC cells and lesser nephrotoxic potential than pazopanib.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Bibian M. E. Tullemans, Sanne L. N. Brouns, Frauke Swieringa, Siamack Sabrkhany, Franchette W. P. J. van den Berkmortel, Natascha A. J. B. Peters, Peter de Bruijn, Stijn L. W. Koolen, Johan W. M. Heemskerk, Maureen J. B. Aarts, Marijke J. E. Kuijpers
Summary: This study investigated the effects of TKI sunitinib on platelet count and function. The results showed that sunitinib can cause a sustained reduction in platelet count and a decrease in platelet aggregation, which is correlated to the inhibitor levels in plasma/serum. The reduced aggregation is associated with bleeding but not disease progression.
Review
Oncology
Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
Summary: Non-clear cell renal cell carcinoma (nccRCC) is a common subtype of renal cell carcinoma, which mainly affects younger patients and often presents with metastasis. The prognosis of nccRCC is generally worse compared to other subtypes. Clinical trials for this subtype are lacking, leading to limited data on response rates and survival outcomes. Current treatment options for nccRCC are still being investigated, often based on extrapolation from studies on clear-cell RCC.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Arkadiusz Z. Dudek, Li C. Liu, James H. Fischer, Elizabeth L. Wiley, Jasgit C. Sachdev, Jonathan Bleeker, Randolph W. Hurley, Debra A. Tonetti, Gregory R. J. Thatcher, Robert P. Venuti, Ruth M. O'Regan
BREAST CANCER RESEARCH AND TREATMENT
(2020)
Article
Oncology
Arkadiusz Z. Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E. Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E. Vokes, Hedy L. Kindler
CLINICAL LUNG CANCER
(2020)
Meeting Abstract
Oncology
R. D. Carvajal, J. S. Weber, A. Z. Dudek, J. Grewal, I. Mehmi, O. Hamid, Y. Du, M. Desai, Y. Wang, L. Sun, J. Rege, M. R. Middleton
ANNALS OF ONCOLOGY
(2021)
Meeting Abstract
Oncology
Arkadiusz Z. Dudek, Dejan Juric, Afshin Dowlati, Erlene Kuizon Seymour, Jordi Rodon Ahnert, Bingxia Wang, Dennis Huszar, Allison J. Berger, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim, Anthony J. Olszanski
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Manish Patel, Shanda H. Blackmon, Arkadiusz Z. Dudek, Naomi Fujioka, Shirley Kern, Nancy Torrison, Pasi A. Janne
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Dylan M. Zylla, Justin Eklund, Grace Gilmore, Alissa Gavenda, Jordan Guggisberg, Gabriela VazquezBenitez, Pamala A. Pawloski, Tom Arneson, Sara Richter, Angela K. Birnbaum, Stephen Dahmer, Matthew Tracy, Arkadiusz Dudek
Summary: The study aimed to investigate the impact of using medical cannabis on pain control in cancer patients. The results showed that patients in the early cannabis group performed better in reducing opioid use and improving pain control, with high satisfaction reported by patients.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Biochemistry & Molecular Biology
Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N. Smith, Archana Balan, James R. White, Christopher Cherry, I. K. Ashok Sivakumar, Xiaoshan M. Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B. Illei, Drew M. Pardoll, Rachel Karchin, Victor E. Velculescu, Julie R. Brahmer, Suresh S. Ramalingam
Summary: The combination of durvalumab with platinum-based chemotherapy shows promising clinical activity in patients with malignant pleural mesothelioma, leading to improved survival rates. Adverse events during treatment were in line with known side effects of chemotherapy, and immunotherapy-induced adverse reactions were mild.
Meeting Abstract
Oncology
Arkadiusz Dudek, Dejan Juric, Afshin Dowlati, Ulka Vaishampayan, Hadeel Assad, Jordi Rodon, Bo Chao, Bingxia Wang, John Gibbs, Vaishali Shinde, Sharon Friedlander, Allison Berger, Christine Ward, Alonzo Martinez, Robert Gharavi, Alejandro Gomez-Pinillos, Igor Proscurshim, Anthony Olszanski
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Melissa Johnson, Arkadiusz Z. Dudek, Ammar Sukari, Justin Call, Paul R. Kunk, Karl Lewis, Justin F. Gainor, John Sarantopoulos, Patrice Lee, Adele Golden, Allison Harney, S. Michael Rothenberg, Yuanyuan Zhang, Jonathan W. Goldman
Summary: This study evaluated the safety and preliminary efficacy of ARRY-382 plus pembrolizumab in patients with advanced solid tumors. The results showed limited clinical benefit, but the combination therapy was well tolerated.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Zhihui Xie, Magne Borset, Kjell Sveen, Ole Wilhelm Boe, Eunice C. Chan, Justin B. Lack, Katherine M. Hornick, Franco Verlicchi, A. Robin Eisch, Remo Melchio, Arkadiusz Z. Dudek, Kirk M. Druey
Summary: This study found that dysfunction of eGCX may contribute to clinical symptoms of acute ISCLS, while endothelial cell injury is not significant. There is a significant difference in the abundance of eGCX-related proteins in plasma between acute and remission phase of ISCLS. Measurement of eGCX components during acute episodes of ISCLS can be used to monitor clinical status and therapeutic responses.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele
Summary: The study found that TKI-resistant ROS1+ NSCLC cells displayed MET amplification without activating mutations. MET amplification was also observed in patient samples receiving ROS1 TKI therapy. This suggests that MET-mediated resistance may occur following treatment with ROS1-selective inhibitors.
Article
Oncology
Oana C. C. Danciu, Matthias Holdhoff, Richard A. A. Peterson, James H. H. Fischer, Li C. C. Liu, Heng Wang, Neeta K. K. Venepalli, Rozina Chowdhery, M. Kelly Nicholas, Meredith J. J. Russell, Timothy M. M. Fan, Paul J. J. Hergenrother, Theodore M. M. Tarasow, Arkadiusz Z. Z. Dudek
Summary: This study is the first-in-human clinical trial of PAC-1, assessing its maximum tolerated dose, safety, and pharmacokinetics. The recommended phase 2 dose of PAC-1 was found to be 750 mg/day. The study also observed clinical activity of PAC-1 in patients with neuroendocrine tumors, suggesting further investigation is warranted.
BRITISH JOURNAL OF CANCER
(2023)
Meeting Abstract
Oncology
G. Saggu, D. Stroopinsky, A. Z. Dudek, A. J. Olszanski, D. Juric, A. Dowlati, U. Vaishampayan, H. Assad, J. Rodon, J. Gibbs, J. Green, Z. Du, R. Rudicell, K. Kannan, R. Gharavi, A. Gomez-Pinillos, R. J. Fram, A. Berger, K. Sachsenmeier, S. Kasar
EUROPEAN JOURNAL OF CANCER
(2022)
Meeting Abstract
Oncology
Jeffrey S. Weber, Richard D. Carvajal, Omid Hamid, Seung Tae Kim, Miso Kim, Ryan J. Sullivan, Dae Ho Lee, Inderjit Mehmi, Jaspreet Singh Grewal, Hyo Jin Lee, Arkadiusz Z. Dudek, Yangchun Du, Monali Desai, Yan Wang, Carlos Alberto Mayo, Mark R. Middleton
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Arjun Vasant Balar, Samuel Aaron Funt, Shilpa Gupta, Arkadiusz Z. Dudek, Alejandro Recio Boiles, Daniel A. Vaena, Deepak Kilari, Jonathan E. Rosenberg
JOURNAL OF CLINICAL ONCOLOGY
(2020)